Finerenone’s New Role in HFpEF and HFmrEF

Dr. James Whitfield

So, so for years, for literally over a decade, we had this massive patient population, right, people with heart failure where the ejection fraction was preserved or mildly reduced, like, ejection fraction of forty percent or greater. And every single time we tried the classic steroidal mineralocorticoid receptor antagonists, like, like spironolactone in the TOPCAT trial, it, it was just a mess. Either the results were mixed or patients had to stop because of severe hyperkalemia or, or gynecomastia and endocrine side effects.

Dr. Elena Rodriguez

Right, spironolactone. The, the endocrine side effects were always the wall we hit because it was so nonselective.

Dr. James Whitfield

Exactly. You give spironolactone for stiff heart chambers, and suddenly your patient has painful breast swelling or their potassium spikes to six point zero. So we were essentially stuck using loop diuretics just to manage fluid overload, while the underlying myocardial stiffness and fibrosis just kept getting worse.

Dr. Elena Rodriguez

And that is precisely why finerenone is such a fascinating compound from a molecular standpoint. It is not a steroid, right. It is a nonsteroidal MRA, meaning its chemical structure is bulky and entirely distinct. When it sits in the mineralocorticoid receptor, it binds with high selectivity. It doesn't cross react with androgen or progesterone receptors at all, which eliminates those hormonal side effects completely. Plus, its binding kinetics are different, it acts as a bulky antagonist that physically prevents the receptor from recruiting pro-fibrotic coactivators.

Dr. James Whitfield

Wait, so, so you get the anti-fibrotic benefit in the heart muscle without the hormone cross-talk?

Dr. Elena Rodriguez

Precisely. That bulky structure changes how the receptor sits, blocking that downstream signaling pathway that leads to remodeling and stiffness. And that pharmacodynamic difference is what set up the FINEARTS HF trial.

Dr. James Whitfield

Which was huge. I mean, six thousand and one patients randomized across the globe. All of them had symptomatic heart failure and an ejection fraction of forty percent or higher. Three thousand and three patients got finerenone, either twenty or forty milligrams daily, and two thousand nine hundred and ninety eight got placebo, both on top of standard therapy, followed for a median of thirty two months.

Dr. Elena Rodriguez

Thirty two months of follow up in a double blind design. And remember, when this trial was running, SGLT2 inhibitors were already becoming standard of care. So the big question in my mind was whether adding finerenone on top of existing therapy would actually show an incremental, additive benefit, or if it would just be redundant mechanism.

Dr. James Whitfield

Well, the paper dropped in the New England Journal of Medicine, and the headline result was clear: in patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of the primary composite endpoint. Specifically, a sixteen percent overall reduction in total worsening heart failure events and cardiovascular death. We saw ten hundred and eighty three events in the finerenone arm compared to twelve hundred and eighty three in the placebo arm. That gave a rate ratio of zero point eight four, with a ninety five percent confidence interval of zero point seven four to zero point nine five, p value zero point zero zero seven.

Dr. Elena Rodriguez

Ten hundred and eighty three versus twelve hundred and eighty three. But, but James, when you pull apart that primary outcome, where did that sixteen percent reduction actually come from?

Dr. James Whitfield

That is the crucial distinction. The benefit was driven almost entirely by an eighteen percent reduction in worsening heart failure events. That was eight hundred and forty two events in the finerenone group versus ten hundred and twenty four in placebo, rate ratio zero point eight two. But when you isolate cardiovascular mortality on its own, it was eight point one percent in the finerenone group versus eight point seven percent in placebo. That gave a hazard ratio of zero point nine three, with a confidence interval ranging from zero point seven eight to one point one one. So a numerical trend down, but, uh, not statistically significant on mortality alone.

Dr. Elena Rodriguez

Right, so it keeps patients out of the hospital and stops urgent clinic visits for decompensation, but it is not necessarily a hard survival drug on its own. And what about the trade-offs? Because nonsteroidal or not, you are still blocking aldosterone receptors in the kidney.

Dr. James Whitfield

Yeah, the kidneys don't care that it is nonsteroidal when it comes to potassium excretion. We saw a significantly higher rate of hyperkalemia in the finerenone group, though interestingly, a significant drop in hypokalemia. But, uh, practically speaking, if you start a patient on finerenone, you cannot just prescribe it and forget it. You need regular lab checks for serum potassium and renal function, especially in patients who are already on ACE inhibitors, ARBs, or who have underlying chronic kidney disease.

Dr. Elena Rodriguez

So in clinical practice, we now have two proven, distinct disease modifying drug classes for HFpEF and HFmrEF: SGLT2 inhibitors and now nonsteroidal MRAs. But implementing both means managing multi-drug regimens and coordinating frequent blood work.

Dr. James Whitfield

Exactly. It gives us a real second pillar of therapy, but we have to be realistic about the monitoring burden. Still, going from zero disease modifying options a few years ago to having SGLT2 inhibitors and now finerenone is a massive paradigm shift for how we treat these patients.

Dr. Elena Rodriguez

A massive shift indeed. Well, that wraps up the breakdown of FINEARTS HF. Good chatting with you, James.

Dr. James Whitfield

Yeah, talk to you next time.